Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $26.17 Average Price Target from Analysts


Share on StockTwits

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have earned an average rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $26.17.

Several analysts have commented on the company. Credit Suisse Group assumed coverage on Mersana Therapeutics in a research note on Tuesday, March 30th. They set a “neutral” rating and a $18.00 price objective for the company. Zacks Investment Research cut Mersana Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 9th.

MRSN traded down $0.68 on Wednesday, hitting $15.97. 458,764 shares of the company were exchanged, compared to its average volume of 1,031,898. Mersana Therapeutics has a twelve month low of $7.66 and a twelve month high of $29.09. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -12.33 and a beta of 2.54. The company has a current ratio of 13.05, a quick ratio of 13.05 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $17.37 and a two-hundred day moving average price of $20.60.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Friday, February 26th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.43 million. Mersana Therapeutics had a negative return on equity of 45.16% and a negative net margin of 8,772.91%. Equities analysts expect that Mersana Therapeutics will post -1.33 EPS for the current year.

In other Mersana Therapeutics news, insider Timothy B. Lowinger sold 8,203 shares of the business’s stock in a transaction that occurred on Wednesday, January 20th. The stock was sold at an average price of $21.54, for a total transaction of $176,692.62. Following the transaction, the insider now owns 33,318 shares in the company, valued at approximately $717,669.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 16,951 shares of company stock worth $331,843 in the last quarter. 5.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRSN. Price T Rowe Associates Inc. MD grew its holdings in shares of Mersana Therapeutics by 80.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,304,346 shares of the company’s stock worth $87,929,000 after acquiring an additional 1,475,727 shares during the period. BlackRock Inc. grew its holdings in shares of Mersana Therapeutics by 10.1% in the 4th quarter. BlackRock Inc. now owns 7,987,812 shares of the company’s stock worth $212,556,000 after acquiring an additional 735,806 shares during the period. Candriam Luxembourg S.C.A. grew its holdings in shares of Mersana Therapeutics by 90.9% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,122,145 shares of the company’s stock worth $29,861,000 after acquiring an additional 534,437 shares during the period. Tri Locum Partners LP acquired a new stake in shares of Mersana Therapeutics in the 4th quarter worth approximately $7,237,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Mersana Therapeutics by 197.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 353,475 shares of the company’s stock worth $6,582,000 after acquiring an additional 234,786 shares during the period.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Featured Story: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.